Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

CRANN partnership with Merck Millipore on research

CRANN, the Science Foundation Ireland funded nanoscience research institute, based at Trinity College Dublin, has today announced a new commercial partnership worth over €130,000 with Merck Millipore, a biotech and pharmaceutical company based in Cork. As part of the research programmes, CRANN will assist Merck Millipore to further develop the nanostructures of their products’ artificial membranes, that are widely used for medical and diagnostic devices, and to deliver new products with improved membrane performances. Artificial membranes are used in a wide array of products such as lab filtration devices, antibody screening kits and blood typing products.

21 Sep 2011

Silence Therapeutics reports revenue of £354,078 for six months ended 30 June 2011

Silence Therapeutics Plc, a leading international RNAi therapeutics company, today provides a corporate update and announces its interim results for the six months ended 30 June 2011.

21 Sep 2011

Preclinical studies shows EmPAC more effective than Taxol

Cornerstone Pharmaceuticals, Inc. has announced the publication of data from preclinical studies on EmPAC™, its nanoparticle reformulation of paclitaxel, in the August issue of the Journal of Nanoscience and Nanotechnology. The publication highlights data demonstrating improved safety and efficacy of EmPAC™ versus Taxol®, the generic formulation of paclitaxel and one of the most widely prescribed chemotherapies. EmPAC™ is a nanoemulsion formulation of Paclitaxel and is the lead product candidate of Cornerstone’s proprietary Emulsiphan™ cancer selective delivery nanotechnology platform. Taxol®, an injectable formulation of Paclitaxel, is currently used to treat a variety of cancers, including ovarian carcinomas, breast cancer, non-small cell lung cancer, and AIDS-related Kaposi’s sarcoma.

19 Sep 2011

Positive Phase 1 data for NovaDigm NDV-3 vaccine presented at 51st ICAAC

NovaDigm Therapeutics, a company developing innovative vaccines for fungal and bacterial infections, today announced the presentation of positive Phase 1 data for its NDV-3 vaccine program at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).

19 Sep 2011

Novartis reports positive results from first pivotal ACZ885 Phase III trial in systemic juvenile idiopathic arthritis

Novartis announced today positive results of the first pivotal Phase III trial of ACZ885 in patients with systemic juvenile idiopathic arthritis (SJIA), a rare and serious childhood auto-inflammatory disease. The results, presented at the 2011 European Pediatric Rheumatology Congress in Bruges, Belgium, showed all primary and secondary endpoints of the study were met.

17 Sep 2011

Follow-up study of HIV vaccine trial provides clues for continued research

"After two years of analyzing the results of the largest AIDS vaccine clinical trial ever held -- called RV144 -- researchers say they have found two ways the immune system can respond, which could predict whether those inoculated will be protected or are more likely to become infected with HIV," CNN's health blog "The Chart" reports.

16 Sep 2011

TCT to showcase major scientific research breakthroughs in cardiovascular medicine

The Cardiovascular Research Foundation has announced the late breaking trials and first report investigations that will be presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2011 scientific symposium. Presented in partnership with the American College of Cardiology (ACC), TCT 2011 is the world's leading educational meeting specializing in interventional cardiovascular medicine and will take place November 7-11, 2011 in San Francisco.

16 Sep 2011

CRF announces late breaking trials & first report investigations to be presented at TCT 2011

The Cardiovascular Research Foundation has announced the late breaking trials and first report investigations that will be presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2011 scientific symposium. Presented in partnership with the American College of Cardiology (ACC), TCT 2011 is the world’s leading educational meeting specializing in interventional cardiovascular medicine and will take place November 7-11, 2011 in San Francisco.

15 Sep 2011

Hengrui, Shanghai ChemPartner enter strategic development partnership for monoclonal antibodies

ShangPharma Corporation, a leading China-based pharmaceutical and biotechnology research and development outsourcing company, and Jiangsu Hengrui Medicine Co., Ltd., a leading Chinese pharmaceutical company, today announced that Shanghai ChemPartner, a wholly owned subsidiary of ShangPharma, and Hengrui have entered into a strategic partnership for the development of novel therapeutic monoclonal antibodies.

15 Sep 2011

Researchers may have solved 100-year-old puzzle to safely open and close the blood-brain barrier

Cornell University researchers may have solved a 100-year puzzle: How to safely open and close the blood-brain barrier so that therapies to treat Alzheimer's disease, multiple sclerosis and cancers of the central nervous system might effectively be delivered.

14 Sep 2011

OBT, Seattle Genetics form strategic collaboration to discover novel ADCs for cancer

Seattle Genetics, Inc. and Oxford BioTherapeutics today announced that they have formed a strategic collaboration to jointly discover novel antibody-drug conjugates (ADCs) for cancer.

14 Sep 2011

Cardiotrophin 1 has marked effect on fat and glucose metabolism

Scientists from the Center for Applied Medical Research (CIMA) of the University of Navarra (Spain) have discovered that cardiotrophin 1, a protein synthesized by muscle cells and adipose tissue, has a marked effect on fat and glucose metabolism.

13 Sep 2011

PharmAthene completes 1,500 liter engineering production run for SparVax anthrax vaccine

PharmAthene, Inc. announced today that it has achieved significant progress in the development of its second generation anthrax vaccine, SparVax.

12 Sep 2011

Black children more at risk for peanut allergy: Study

U.S. researchers examined the genetic profiles of more than 1,100 urban children of different races, averaging around 3 years of age, and found that black children were more likely to have allergic antibodies to food allergens. The study also found that African ancestry was linked with levels of allergic antibodies to peanut typically associated with clinical peanut allergies.

9 Sep 2011

Landmark discovery in rapid spread of PRL-3 oncoprotein associated aggressive cancers

Scientists at A*STAR's Institute of Molecular and Cell Biology (IMCB) have made a landmark discovery in the battle against the rapid spread of aggressive cancers associated with PRL-3 oncoprotein.

9 Sep 2011

Stage III lung cancer patients can benefit from concurrent chemo and radiation therapy

Nearly 50,000 Americans are diagnosed each year with stage III or locally advanced NSCLC, for which surgery is usually not a viable treatment option. Optimizing nonsurgical treatment strategies for these patients is an ongoing research endeavor.

9 Sep 2011

Elusys receives federal contract to develop prophylactic treatment against anthrax

Elusys Therapeutics, Inc., a biopharmaceutical company developing biodefense countermeasures, announced today that it has been awarded the first U.S. Government contract to develop an anti-toxin for pre- and post-exposure prophylaxis (PEP) use via intramuscular injection.

9 Sep 2011

Scientists discover backup circuits in cetuximab-resistant cancer cells

Scientists at Dana-Farber Cancer Institute and colleagues overseas have discovered a pair of backup circuits in cancer cells that enable the cells to dodge the effect of a widely used cancer drug.

8 Sep 2011

Researchers discover mechanism of low-dose LDN on cell proliferative-related disorders

Researchers at The Pennsylvania State University College of Medicine, Hershey, Pennsylvania have discovered the mechanism by which a low dose of the opioid antagonist naltrexone (LDN), an agent used clinically to treat cancer and autoimmune diseases, exerts a profound inhibitory effect on cell proliferation.

3 Sep 2011

Researchers discover protein signals responsible for preserving anti-viral antibodies

Our immune system is capable of a remarkable feat: the ability to remember infections for years, even decades, after they have first been encountered and defeated. While the antibodies we make last only about a month, we retain the means of making them for a lifetime.

3 Sep 2011

Antibody News and Research

Further Reading

CRANN partnership with Merck Millipore on research

Silence Therapeutics reports revenue of £354,078 for six months ended 30 June 2011

Preclinical studies shows EmPAC more effective than Taxol

Positive Phase 1 data for NovaDigm NDV-3 vaccine presented at 51st ICAAC

Novartis reports positive results from first pivotal ACZ885 Phase III trial in systemic juvenile idiopathic arthritis

Follow-up study of HIV vaccine trial provides clues for continued research

TCT to showcase major scientific research breakthroughs in cardiovascular medicine

CRF announces late breaking trials & first report investigations to be presented at TCT 2011

Hengrui, Shanghai ChemPartner enter strategic development partnership for monoclonal antibodies

Researchers may have solved 100-year-old puzzle to safely open and close the blood-brain barrier

OBT, Seattle Genetics form strategic collaboration to discover novel ADCs for cancer

Cardiotrophin 1 has marked effect on fat and glucose metabolism

PharmAthene completes 1,500 liter engineering production run for SparVax anthrax vaccine

Black children more at risk for peanut allergy: Study

Landmark discovery in rapid spread of PRL-3 oncoprotein associated aggressive cancers

Stage III lung cancer patients can benefit from concurrent chemo and radiation therapy

Elusys receives federal contract to develop prophylactic treatment against anthrax

Scientists discover backup circuits in cetuximab-resistant cancer cells

Researchers discover mechanism of low-dose LDN on cell proliferative-related disorders

Researchers discover protein signals responsible for preserving anti-viral antibodies

Event guide: 5th Novel Conjugates Summit 2026 eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo